Gastrointestinal distress, specifically nausea and emesis, represents a highly prevalent clinical phenomenon in early gestation, impacting approximately 70 to 80% of gravidae globally [1]. Hyperemesis gravidarum (HG) occupies the most critical threshold of this pathological continuum, defined by intractable, continuous vomiting that precipitates profound hypovolemia, serum electrolyte disturbances, ketonuria, severe nutritional depletion, and substantial maternal mass reduction [1-4]. While the precise underlying etiology driving HG is yet to be fully elucidated, contemporary clinical data point toward a multifactorial origin driven by interconnected endocrine, metabolic, immune-mediated, gastric motility, hereditary, and psychological dynamics [1,5-12]. This clinical state yields substantial maternal morbidity and carries the potential to compromise fetal development and obstetric outcomes if accurate diagnosis and therapeutic interventions are delayed [5].

Progress within maternal-fetal medicine has increasingly emphasized the role of nutritional depletion and biochemical shifts in driving the pathological progression of HG. Severe intractable emesis combined with restricted nutritional intake during the initial trimester frequently precipitates acute micronutrient deficits and systemic metabolic disturbances [9,13, 14]. Within this scope, anomalies in iron homeostasis and vitamin B12 dynamics are receiving heightened clinical scrutiny due to their capacity to impact maternal physiology, trophoblast function, cellular oxidative stress, and embryonic organogenesis [8,9].

Ferritin, functioning as the primary intracellular reservoir for iron, operates as both an indicator of total bodily iron reserves and an acute-phase reactant that undergoes upregulation during systemic inflammatory responses and oxidative stress [1]. Heightened circulating ferritin concentrations have been correlated with low-grade systemic inflammation, hepatic parenchyma stress, and metabolic dysregulation across multiple obstetric complications. In patients presenting with HG, prolonged nutritional deprivation, volume depletion, and localized tissue stress may disrupt standard ferritin metabolic pathways, driving an increase in peripheral ferritin concentrations [3]. Nonetheless, current medical literature documenting ferritin dynamics in the context of HG remains scarce and contradictory, particularly within developing nations where pre-existing gestational malnutrition is highly prevalent.

Vitamin B12 represents a crucial water-soluble micronutrient indispensable for cellular DNA replication, red blood cell production, myelin integrity, and fetal central nervous system development. Inadequate maternal vitamin B12 status throughout gestation has been definitively associated with megaloblastic anemia, peripheral neuropathy, restricted fetal growth, neural tube anomalies, and long-term neurocognitive deficits in pediatric cohorts [8]. The unyielding vomiting and secondary dietary restriction characteristic of HG place these patients at elevated risk for rapid vitamin B12 exhaustion. Despite these profound clinical ramifications, a limited number of trials have systematically investigated vitamin B12 concentrations among first-trimester HG cohorts, especially within Indian demographics where baseline nutritional vulnerabilities are widespread.

Endocrine dysregulation involving the thyroid axis represents another critical biochemical anomaly frequently intersecting with HG. Human chorionic gonadotropin (hCG), which achieves peak circulating levels during the first trimester, exhibits structural homology with thyroid-stimulating hormone (TSH), allowing it to bind and activate TSH receptors, thereby stimulating thyrocyte activity [5]. As a result, self-limiting gestational thyrotoxicosis manifesting as suppressed serum TSH alongside elevated free thyroxine (FT4) concentrations is regularly documented in patients with severe HG presentations [4,5]. Prior investigations have detailed inconsistent degrees of thyrometabolic deviations in HG cases, though the precise nexus connecting thyroid dysfunction, trace element depletion, and clinical symptom severity requires clearer definition [2,5].

The simultaneous presentation of aberrant ferritin levels, vitamin B12 depletion, and thyroid axis abnormalities likely underscores a highly intricate metabolic, nutritional, and inflammatory crosstalk in HG pathology. Prompt recognition of these combined biochemical variations could optimize clinical pathways, streamline targeted nutritional replacement therapy, and mitigate severe maternal morbidities stemming from prolonged gestational emesis. Unfortunately, clinical trials evaluating these specific serum biomarkers concurrently within a single HG cohort remain highly limited, particularly within the Indian healthcare context.

Consequently, this prospective clinical investigation was established to quantify and analyze serum ferritin, vitamin B12, and thyroid hormone parameters in first-trimester gravidae diagnosed with hyperemesis gravidarum, benchmarking these values against a matched cohort of healthy, uncomplicated pregnancies. This research sought to deepen the current understanding of the complex endocrine and metabolic shifts unique to HG, while exploring their broader clinical consequences during early gestation.

MATERIALS & METHODS:

This clinical investigation utilized a hospital-centered, comparative cross-sectional, observational framework, executed by the Department of Obstetrics and Gynecology in tandem with the Department of Biochemistry at a tertiary-level academic medical center. The research spanned a consecutive 12-month duration following formal authorization from the Institutional Ethics Committee. Every protocol requiring human subject involvement strictly adhered to the ethical frameworks established by the institutional review board as well as the tenets of the Declaration of Helsinki. Prior to final study registration, formal written informed consent was explicitly secured from each individual participant.

Study Population

The clinical trial enrolled a total of 120 gravidae during their first trimester of gestation (less than or equal to 12 weeks of development), allocating them equally into two parallel cohorts:

Group I (Cases): Sixty patients presenting with a clinical diagnosis of hyperemesis gravidarum.

Group II (Controls): Sixty healthy pregnant females, matched carefully for both chronological age and gestational duration, experiencing uncomplicated pregnancies free from debilitating emesis or severe nausea.

The clinical confirmation of hyperemesis gravidarum was determined by the presentation of intractable, unyielding nausea and vomiting coupled with a total failure to tolerate sufficient oral nourishment, documented weight reduction surpassing 5 percent of their baseline pre-gravid mass, clinical dehydration, the presence of ketonuria, or an absolute clinical necessity for inpatient hospitalization during the initial trimester of pregnancy.

Inclusion Criteria

Maternal subjects aged between 18 and 35 years old. Confirmed singleton intrauterine gestation within the initial trimester of development. Patients presenting with an established clinical diagnosis of hyperemesis gravidarum designated for the case cohort. Systemically healthy gravidae experiencing an uncomplicated, normal gestation designated for the control cohort. Individuals exhibiting a willingness to actively participate in the investigation and provide formal written informed consent.

Exclusion Criteria

Maternal subjects presenting with pre-existing thyroid dysfunction, diabetes mellitus, chronic hepatic disorders, nephropathy, gastrointestinal pathology, hematological anomalies, or systemic autoimmune conditions. Individuals undergoing therapeutic supplementation with iron, vitamin B12, or exogenous thyroid hormones prior to study entry. Gestations complicated by multiple fetuses, hydatidiform molar pregnancies, or documented embryonic malformations. Patients with a documented history of tobacco smoking, ethanol intake, or long-standing systemic diseases. Women exhibiting acute infectious processes or active systemic inflammatory states.

Clinical Evaluation

A comprehensive clinical anamnesis was gathered from each study participant utilizing a standardized, preformulated questionnaire. Specific parameters concerning maternal age, parity, gestational duration, socioeconomic classification, nutritional patterns, the timeline and severity of emesis, mass reduction, and prior reproductive outcomes were documented. Systemic physical evaluations alongside routine obstetric examinations were executed across all enrolled subjects. Baseline body mass and height parameters were quantified through validated anthropometric methodologies, allowing for the determination of the body mass index (BMI).

Laboratory Investigations

Utilizing sterile surgical techniques, a fasting peripheral venous blood draw of roughly 5 mL was obtained from every individual participant. Collected specimens were left undisturbed to facilitate coagulation and subsequently spun down via centrifugation at 3000 rpm for a duration of 10 minutes to isolate the serum layer. These separated serum fractions underwent immediate processing or were cryopreserved at minus 20 degrees Celsius pending subsequent laboratory evaluation. Quantitative measurement of serum ferritin was executed employing the chemiluminescent microparticle immunoassay (CMIA) technique. Peripheral vitamin B12 concentrations were determined through electrochemiluminescence immunoassay (ECLIA) testing. Comprehensive thyroid status profiles, encompassing TSH, FT3, and FT4, were quantified on fully automated immunoassay platforms in strict compliance with commercial manufacturer directives and established laboratory operating protocols. Rigorous quality assurance protocols were enforced across the entire analytical timeline via the deployment of internal reference controls and systematic instrument calibration methods.

Outcome Measures

The main endpoints established for this research focused on evaluating variations in circulating concentrations of serum ferritin, vitamin B12, TSH, FT3, and FT4 between the hyperemesis gravidarum patient cohort and the unaffected gestational control subjects. Collateral endpoints involved calculating the specific incidence rates of hyperferritinemia, vitamin B12 insufficiency, suppressed TSH production, and temporary biochemical gestational thyrotoxicosis presenting across the comparative clinical groups.

Statistical Analysis

Gathered metrics were systematically compiled into a Microsoft Excel spreadsheet and processed employing the Statistical Package for the Social Sciences (SPSS) software version 25.0 (IBM Corp., Armonk, NY, USA). Continuous parametric values were reported as mean +/- standard deviation (SD), whereas categorical distributions were stated via absolute frequencies and percentages. Evaluation of continuous data points across the two clinical cohorts was completed utilizing the independent Student’s t-test for normally distributed parameters. For nominal or categorical data, the Chi-square test or Fisher’s exact test was deployed based on analytical suitability. A p-value less than 0.05 established the threshold for statistical significance.

RESULTS:

Table 1. Demographic and Obstetric Characteristics of Study Participants

*Statistically significant (p < 0.05)

Demographic and reproductive attributes of the enrolled subjects are summarized within Table 1. The average chronological age for the hyperemesis gravidarum cohort was documented at 25.8 +/- 3.7 years, whereas the control cohort presented an average of 26.2 +/- 3.9 years, demonstrating an absence of a mathematically meaningful variation across cohorts (p = 0.564). Along similar lines, the mean gestational duration was highly balanced between patients with hyperemesis gravidarum (9.4 +/- 1.8 weeks) and the healthy control cohort (9.7 +/- 1.6 weeks) (p = 0.318). First-time mothers (primigravidae) made up 63.3 percent of the hyperemesis cohort relative to 51.7 percent within the control baseline; nevertheless, this distribution did not yield a statistically significant variation (p = 0.201). Conversely, the calculated mean body mass index was found to be notably depressed among gravidae presenting with hyperemesis gravidarum (21.4 +/- 2.6 kg/m-squared) compared to the control subjects (22.7 +/- 2.9 kg/m-squared) (p = 0.014). Patients struggling with hyperemesis gravidarum endured a substantially greater absolute mass reduction from their pre-gravid state (3.8 +/- 1.4 kg) than did the control participants (0.9 +/- 0.5 kg) (p less than 0.001). Additionally, the daily occurrence rate of emesis episodes was markedly elevated in the hyperemesis cohort (7.2 +/- 2.1 events per day) versus the comparative group (1.1 +/- 0.7 events per day) (p less than 0.001). Finally, acute inpatient hospitalization was necessitated for 43.3 percent of individuals within the hyperemesis cohort compared with a mere 3.3 percent of the control cohort, reflecting an exceptionally high level of statistical significance (p less than 0.001).

Table 2. Comparison of Serum Ferritin and Vitamin B12 Levels Between Groups

*Statistically significant (p < 0.05)

A comparative analysis of vitamin B12 and serum ferritin concentrations between the hyperemesis gravidarum patients and the control cohort is presented in Table 2. The average circulating ferritin concentration was markedly increased among maternal subjects presenting with hyperemesis gravidarum (82.6 +/- 24.3 ng/mL) relative to the healthy, uncomplicated control subjects (46.8 +/- 18.5 ng/mL) (p less than 0.001). Conversely, systemic vitamin B12 concentrations were profoundly depressed within the hyperemesis gravidarum cohort (214.5 +/- 61.2 pg/mL) when benchmarked against the corresponding reference group (318.9 +/- 74.6 pg/mL) (p less than 0.001). Hyper-ferritinemia, established as serum ferritin values exceeding 70 ng/mL, was identified in 65.0 percent of individuals suffering from hyperemesis gravidarum, whereas a mere 18.3 percent of the control participants exhibited comparable values, reflecting a highly meaningful statistical divergence (p less than 0.001). Furthermore, vitamin B12 insufficiency characterized by circulating values falling under 200 pg/mL was confirmed in 45.0 percent of the hyperemesis gravidarum cohort versus 13.3 percent of the control subjects, an asymmetry that similarly achieved strong statistical significance (p less than 0.001)..

Table 3. Comparison of Thyroid Profile Between Hyperemesis Gravidarum and Control Groups

The comparative distribution of the maternal thyroid axis between the hyperemesis gravidarum cohort and uncomplicated gestational controls is outlined in Table 3. The average circulating thyroid-stimulating hormone (TSH) concentration was markedly diminished within the hyperemesis gravidarum cohort (0.68 +/- 0.41 mIU/L) in comparison to the control arm (1.72 +/- 0.63 mIU/L) (p less than 0.001). Conversely, both FT3 and FT4 parameters were substantially increased among patients experiencing hyperemesis gravidarum. The average FT3 concentration was recorded at 3.9 +/- 0.8 pg/mL in the hyperemesis gravidarum group relative to 3.1 +/- 0.5 pg/mL among the control subjects (p less than 0.001). Parallel to this trend, the mean FT4 value was significantly elevated in the hyperemesis gravidarum cohort (1.71 +/- 0.34 ng/dL) versus the healthy baseline cohort (1.29 +/- 0.22 ng/dL) (p less than 0.001). Depressed TSH concentrations falling below 0.4 mIU/L were identified in 40.0 percent of individuals with hyperemesis gravidarum compared with a mere 6.7 percent of the control counterparts, establishing a notable statistical variance (p less than 0.001). Furthermore, self-limiting biochemical gestational thyrotoxicosis was confirmed in 18.3 percent of the hyperemesis gravidarum patients, whereas only 1.7 percent of the healthy control participants exhibited this manifestation (p = 0.002).

DISCUSSION:

Severe intractable emesis during the initial trimester of development defines HG, a clinical pathology that drives profound hypovolemia, serum electrolyte disruption, micronutrient depletion, and systemic metabolic derangements. Although its precise cellular etiopathogenesis is not yet completely unraveled, a combination of endocrine, immune-mediated, dietary, and neurological pathways have been structurally tied to its clinical progression [1]. This clinical trial quantified circulating concentrations of serum ferritin, vitamin B12, and the maternal thyroid axis among first-trimester gravidae presenting with hyperemesis gravidarum, evaluating these parameters against unaffected gestational control individuals. Our laboratory outcomes revealed a profound elevation in serum ferritin levels, a significant depletion of vitamin B12 concentrations, suppressed pituitary TSH output, and significantly increased peripheral FT3 and FT4 levels within the symptomatic HG group.

Within this research cohort, patients suffering from hyperemesis gravidarum manifested substantially accelerated maternal weight reduction, heightened daily frequencies of emesis events, and remarkably higher relative rates of inpatient clinical admission compared to the healthy control cohort. These observations run parallel to the standardized clinical spectrum of HG described across contemporary international meta-analyses and professional obstetrical guidelines, which document severe intractable vomiting, volume depletion, nutritional exhaustion, and maternal mass reduction as hallmark diagnostic indices of the pathology [1,5]. Corresponding dynamics were documented by a prior clinical trial that highlighted the intense metabolic stress and nutritional depletion generated by unyielding emesis throughout early pregnancy [1]. The depressed body mass index recorded within our active HG cohort likely reflects a secondary consequence of severe dietary restriction and heightened catabolic pathways brought about by persistent vomiting.

A primary insight derived from this clinical investigation was the markedly heightened concentration of circulating serum ferritin in the HG cohort relative to unaffected controls. Ferritin operates as an acute-phase reactant protein, capable of undergoing significant upregulation in response to low-grade systemic inflammation, cellular oxidative stress, or underlying hepatic parenchymal strain. Consequently, elevated ferritin values in HG patients may indicate a stress-induced inflammatory phenotype rather than reflecting an optimization of maternal iron reservoirs. This hypothesis aligns with multiple independent studies exploring oxidative and inflammatory signaling cascades in HG cohorts, where increased ferritin presentation was directly tied to clinical severity and localized tissue distress [1,3]. Furthermore, starvation-induced ketonuria, intracellular dehydration, and modified hepatic metabolic pathways common to HG may collectively drive this hyperferritinemia. In stark contrast, clinical data investigating uncomplicated pregnancies typically report a gradual contraction of iron reserves and lowered ferritin concentrations across gestation due to the compounding demands of the maternal-fetal unit [2]. Thus, the increased ferritin values observed in this research appear intrinsically tied to the pathological metabolic shifts unique to HG rather than representing standard physiological adaptations of pregnancy.

The current investigation also demonstrated a profound reduction in baseline vitamin B12 concentrations among gravidae presenting with HG, with nearly half of these symptomatic patients reaching the threshold for biochemical vitamin B12 insufficiency. This clinical presentation can be traced to inadequate oral nutrient intake, recurrent emesis, disrupted gastrointestinal mucosal absorption, and naturally elevated maternal-fetal metabolic requirements during early embryogenesis. Vitamin B12 remains a fundamental requirement for cellular DNA replication, red blood cell erythropoiesis, and central nervous system integrity, meaning its exhaustion during gestation can compromise both maternal health and embryonic development. Similar patterns of depleted vitamin B12 concentrations among pregnant populations have been historically recorded across Indian clinical trials evaluating gestational malnutrition [2,8]. Furthermore, prior research has noted a distinct correlation connecting altered thyroid function and diminished vitamin B12 reserves among expectant mothers [8]. Global academic literature similarly highlights the critical nature of trace element and micronutrient exhaustion in HG, specifically pinpointing deficiencies in thiamine, folate, and vitamin B12 stemming from continuous emesis and secondary starvation [1,9].

Another crucial observation within this research was the significant deviation of the thyroid axis among women diagnosed with HG. Serum TSH concentrations were markedly suppressed, while peripheral FT3 and FT4 values were substantially increased in the HG cohort relative to healthy pregnant controls. Additionally, the prevalence of suppressed pituitary TSH and temporary biochemical gestational thyrotoxicosis was significantly higher in the hyperemesis cohort, lending weight to the physiological model of transient gestational hyperthyroidism secondary to HG. hCG, which peaks in concentration during the initial trimester, shares structural homology with thyroid-stimulating hormone (TSH), giving it the capacity to bind and trigger the TSH receptor via molecular cross-reactivity [5]. Elevated circulating hCG levels in HG patients may therefore downregulate pituitary TSH synthesis while driving up peripheral concentrations of active FT3 and FT4.

A multitude of prior clinical trials have demonstrated an identical connection linking HG to self-limiting hyperthyroid biochemistry. Modern obstetric protocols formally acknowledge that biochemical gestational thyrotoxicosis can manifest in severe HG cases in the complete absence of any underlying intrinsic thyroid disease [5]. A separate study conducted among expectant mothers also identified key linkages connecting maternal thyroid deviations with trace element and micronutrient abnormalities throughout gestation [2]. Nevertheless, in contrast to our current findings, certain older Indian clinical surveys reported elevated TSH values alongside depressed thyroid hormone parameters in general obstetric groups, particularly among cohorts presenting with baseline malnutrition and endemic hypothyroidism [2]. This analytical divergence is likely explained by differences across the investigated populations, baseline disease severity, exact gestational age at screening, regional iodine adequacy, and specific study parameters. This research specifically isolated gravidae with an established clinical diagnosis of hyperemesis gravidarum, a state where transient hyperthyroid physiology is far more regularly encountered.

The simultaneous presentation of hyperferritinemia, vitamin B12 insufficiency, and thyroid axis alterations identified in this clinical study implies the existence of a highly sophisticated metabolic and biochemical crosstalk in HG. Micro-nutritional exhaustion may compound existing endocrine dysregulation, while thyroid axis deviations can further exacerbate systemic metabolic strain and the clinical severity of emesis. Evolving medical data suggests that cellular oxidative stress and upstream inflammatory pathways may actively participate in the underlying pathophysiology of HG and its secondary biochemical anomalies [1]. The concurrent observation of elevated ferritin alongside depressed vitamin B12 concentrations supports the hypothesis that systemic inflammatory activation and severe nutritional depletion occur synchronously during this disorder.

The outcomes of this clinical investigation provide highly meaningful ramifications for ongoing obstetric care. Early biochemical and laboratory screening of patients presenting with severe gestational nausea and vomiting could prove pivotal in identifying trace element depletion and thyroid axis anomalies prior to their progression into critical maternal or fetal complications. Implementing routine screening for vitamin B12 insufficiency and thyroid alterations during the initial trimester could streamline target nutritional replenishment and endocrine management pathways, especially for high-risk patients requiring inpatient admission. Such clinical measures could optimize overall maternal health and potentially decrease the incidence of adverse obstetric outcomes.

Certain inherent constraints characterize this clinical research. The patient cohort size was somewhat restricted, and parameters such as serum hCG concentrations, systemic inflammatory markers, and precise dietary records were not quantified. Furthermore, the observational, cross-sectional framework prevents the establishing of direct causal pathways for the documented biochemical correlations. Future multi-institutional longitudinal trials incorporating expanded cohorts and advanced molecular biomarkers are required to achieve a more profound understanding of the pathophysiological mechanism linking hyperemesis gravidarum with micronutrient exhaustion and thyroid axis dysregulation.

CONCLUSION:

This clinical investigation established that first-trimester gravidae presenting with hyperemesis gravidarum manifest markedly elevated serum ferritin concentrations, diminished vitamin B12 reserves, and a modified maternal thyroid axis defined by suppressed pituitary TSH alongside increased circulating FT3 and FT4 values. These laboratory outcomes indicate that the pathophysiology of HG involves profound endocrine and metabolic derangements that extend far beyond standard gestational nausea and emesis. Prompt identification and therapeutic remediation of these underlying biochemical variations could prove highly beneficial in optimizing both maternal health and fetal development.

Conflict of interest:

There is no conflict of interest among the present study authors.

REFERENCES:

1. Liu C, Zhao G, Qiao D, Wang L, He Y, Zhao M, Fan Y, Jiang E. Emerging progress in nausea and vomiting of pregnancy and hyperemesis gravidarum: challenges and opportunities. Frontiers in medicine. 2022 Jan 10;8:809270.
2. Patel V, Singh S, Saxena Y. Corellation between Iron Deficiency Anemia and Thyroid Dysfunction in Pregnancy-A Cross Sectonal Study. CME Journal Geriatric Medicine. 2025 Feb 28;17:80-4.
3. Fejzo MS, Magtira A, Schoenberg FP, MacGibbon K, Mullin P, Romero R, Tabsh K. Antihistamines and other prognostic factors for adverse outcome in hyperemesis gravidarum. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2013 Sep 1;170(1):71-6.
4. Nana M, Painter R, Williamson C, Nelson-Piercy C. Hyperemesis gravidarum. The Lancet. 2026 Jan 3;407(10523):78-89.
5. Jansen LA, Shaw V, Grooten IJ, Koot MH, Dean CR, Painter RC. Diagnosis and treatment of hyperemesis gravidarum. Cmaj. 2024 Apr 15;196(14):E477-485.
6. Lowe SA, Steinweg KE. Management of hyperemesis gravidarum and nausea and vomiting in pregnancy. Emergency Medicine Australasia. 2022 Feb;34(1):9-15.
7. de Tejada BM, Vonzun L, Von Mandach DU, Burch A, Yaron M, Hodel M, Surbek D, Hoesli I. Nausea and vomiting of pregnancy, hyperemesis gravidarum. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2025 Jan 1;304:115-20.
8. Kumar KA, Lalitha A, Pavithra D, Padmavathi IJ, Ganeshan M, Rao KR, Venu L, Balakrishna N, Shanker NH, Reddy SU, Chandak GR. Maternal dietary folate and/or vitamin B12 restrictions alter body composition (adiposity) and lipid metabolism in Wistar rat offspring. The Journal of nutritional biochemistry. 2013 Jan 1;24(1):25-31.
9. Nijsten K, van der Minnen L, Wiegers HM, Koot MH, Middeldorp S, Roseboom TJ, Grooten IJ, Painter RC. Hyperemesis gravidarum and vitamin K deficiency: a systematic review. British Journal of Nutrition. 2022 Jul;128(1):30-42.
10. Gerede A, Stavros S, Moustakli E, Potiris A, Orgianelis I, Zikopoulos A, Drakakis P, Domali E, Eleutheriades M, Nikolettos N. Hyperemesis in Pregnancy: Complications and Treatment. Medical Sciences. 2025 Aug 14;13(3):132.
11. Simanjuntak TP, Andrian SA, Wibowo R, Kurniawan SA, Elingasari NM. Hyperemesis gravidarum: A holistic review and approach to etiopathogenesis, clinical diagnostic and management therapy. Journal of South Asian Federation of Obstetrics and Gynaecology. 2019 Jul 1;11:266-72.
12. Fejzo MS, Sazonova OV, Sathirapongsasuti JF, Hallgrímsdóttir IB, Vacic V, MacGibbon KW, Schoenberg FP, Mancuso N, Slamon DJ, Mullin PM. Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum. Nature communications. 2018 Mar 21;9(1):1178.
13. Fejzo M, Rocha N, Cimino I, Lockhart SM, Petry CJ, Kay RG, Burling K, Barker P, George AL, Yasara N, Premawardhena A. GDF15 linked to maternal risk of nausea and vomiting during pregnancy. Nature. 2024 Jan 25;625(7996):760-7.
14. Elkins JR, Oxentenko AS, Nguyen LA. Hyperemesis gravidarum and nutritional support. Official journal of the American College of Gastroenterology| ACG. 2022 Oct 1;117(10S):2-9.
15. Vinnars MT, Forslund M, Claesson IM, Hedman A, Peira N, Olofsson H, Wernersson E, Ulfsdottir H. Treatments for hyperemesis gravidarum: A systematic review. Acta obstetricia et gynecologica Scandinavica. 2024 Jan;103(1):13-29.